NovoCure (NVCR) reported a Q2 net loss Thursday of $0.13 per diluted share, narrowing from a loss of $0.36 a year earlier.

Analysts polled by FactSet expected a loss of $0.33.

Revenue for the quarter ended June 30 was $183.6 million, compared with $158.8 million a year earlier.

Analysts polled by FactSet expected $172.4 million.

The company has raised 2026 revenue guidance to $710 million to $725 million from the prior guidance of $690 million to $710 million.

Analysts polled by FactSet expect $708.7 million.

Shares of the company were nearly 11% higher in premarket activity.